Company Overview
Snapshot
Founded in January 2023 by Michael Vaknin, Lior Nissim, and Chezy Barenholtz, ViVac operates with 1–10 employees. The company is developing a nucleic acid-based vaccine platform and in November 2025 appointed Keren Leshem as Chief Executive Officer to strengthen its leadership.
Business overview
ViVac is advancing a viral vaccine platform designed to provide robust and long-lasting immunity against viral infections. The company's core technology focuses on nucleic acid-based vaccines that mimic actual viral infections, aiming to offer advantages over mRNA/DNA and traditional vaccines in terms of durability and cost-effective production. ViVac operates within the Health Tech & Life Sciences sector, specifically targeting the pharmaceutical and medical biotechnology industries with its drug delivery solutions.
Strategic signal
In November 2025, ViVac appointed Keren Leshem as Chief Executive Officer. This strategic leadership addition signals the company's focus on strengthening its executive team to advance its RNA–Lipid Nanoparticle (LNP) immunotherapy platform, indicating a push towards further development and potential commercialization in the competitive vaccine and immunotherapy market.
Log in to access full profile ›Company Intelligence Q&A
- What is ViVac's core technology?
- ViVac is developing a revolutionary viral vaccine platform based on nucleic acids. This platform is designed to safely and precisely mimic actual viral infections to immunize against all viral proteins, aiming for more robust and long-lasting immunity compared to existing vaccine technologies.
- When was ViVac founded and by whom?
- ViVac was founded in January 2023 by Michael Vaknin, Lior Nissim, and Chezy Barenholtz, who are experts in synthetic biology and nano drug delivery.
- What is the primary goal of ViVac's vaccine platform?
- The primary goal of ViVac's platform is to provide more robust and long-lasting immunity than mRNA/DNA and traditional vaccines, while also maintaining cost-effective production and enabling scalability to address new viral threats.
- What product is ViVac currently developing?
- ViVac is currently developing a nucleic-acid-based viral vaccine specifically for RSV and Hepatitis C.
- Has ViVac made any recent leadership appointments?
- Yes, in November 2025, ViVac appointed Keren Leshem as Chief Executive Officer to strengthen its leadership and advance its RNA–Lipid Nanoparticle (LNP) immunotherapy platform.